Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

Watch Fireside Chat Below, oregon Click HERE:

IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, President and Chief Operations Officer, moderated by IPO Edge Editor-in-Chief John Jannarone successful a video league lasting astir 30 minutes.

The institution precocious signed a definitive licensing statement with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented formulation of MDMA. The deal, valued astatine up to $100 cardinal including milestones, transforms Jupiter into a dual clinical-stage CNS company, adding ALA-002 to its existing Phase II Parkinson's illness program.

Mr. Rosén and Ms. Silva discussed:

• The caller acquisition successful the psychedelics tract of ALA-002, a patented, non-racemic MDXX molecule for which the institution present owns the exclusive U.S. license.

• Status of the company's Phase 2 proceedings successful Parkinson's Disease

• The superior denotation for ALA-002 and wherever it mightiness beryllium applied, its addressable marketplace size, and its imaginable gross successful examination to the outgo of the acquisition

• How objective trials volition look successful the U.S. successful coming years

• The U.S. authorities presumption regarding the psychedelics tract

• Milestones investors should beryllium focused connected crossed the company's portfolio, including JOTROL

WATCH MORE

$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live astatine Nasdaq

About Christer Rosén

Mr. Rosén is co-founder, Chief Executive Officer and Chairman of the Board of Directors of Jupiter Neurosciences, Inc. since January 1, 2016. Mr. Rosén is simply a serial entrepreneur and has started respective businesses successful assorted industries. From 1997 done May 2015, Mr. Rosén founded and served arsenic the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. At EffRx Mr. Rosén, unneurotic with an experiences pharmaceutical team, invented, developed and received FDA and EU approvals of a cause treating osteoporosis, Binosto. Binosto is distributed successful respective parts of the satellite and gave Mr. Rosén a afloat penetration successful each the aspects of pharmaceutical development, regulatory paths and worldwide distribution. EffRx was acquired successful 2023 by Abiogen SA.

Mr. Rosén is simply a postgraduate of Malmo Trade Schools/Lund University, Sweden, with a grade successful Computer Sciences successful 1971.

WATCH MORE

REPLAY: Fireside Chat with West Point Gold CEO Derek Macpherson

About Alison Silva

Alison D. Silva is the President and Chief Operating Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). She is besides the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer astatine Synlogic, Inc. wherever she pb the regulatory strategy, cause development, and operational aspects of the company's absorption connected the find and improvement of engineered therapeutic probiotics. Alison is besides a co‐founder of The Orphan Group, a specialty consulting institution focused connected assisting companies with processing and implementing their orphan cause strategy and merchandise lifecycle management.